tbuckley/cabot-search huggingface dataset:
Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.
Authors: Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier, Nicoletta Colombo, Domenica Lorusso, Petronella Ottevanger, Maria Bjurberg, Christian Marth, Pilar Barretina-Ginesta, Ignace Vergote, Anne Floquet, Jose Maria Del Campo, Sven Mahner, Lydie Bastiere-Truchot, Lada Mitchell, Sandra Polleis, Andreas Du Bois, Antonio Gonzalez-Martin
Journal: Journal of Clinical Oncology (2015)

5504 Background: Adding P to gemcitabine (GEM) for PROC improved progression-free survival (PFS) in a subset of patients (pts) with low tumor HER3 mRNA expression [Makhija 2010]. Methods: Eligible pts had recurrent PROC (progression [PD] during/within 6 mo of completing ≥ 4 platinum cycles) with centrally tested low tumor HER3 mRNA expression (concentration ratio ≤ 2.81 by qRT-PCR on cobas z480) and ≤ 2 prior CT lines. Investigators (INVs) chose CT (topotecan [TOP], paclitaxel [PAC] or GEM); recruitment was capped to ensure similarly sized CT cohorts. Pts were stratified by chosen CT, prior anti-angiogenic therapy and platinum-free interval ( < 3 vs 3–6 mo) and randomized 1:1 to CT with either placebo or P 840→420 mg q3w until PD/unacceptable toxicity. The primary objective was to determine if independent review committee (IRC)-assessed PFS was superior with P + CT vs placebo + CT. The prespecified primary PFS analysis after 109 blinded IRC-assessed PFS events in 154 planned pts provided 95% power to detect a PFS hazard ratio (HR) of 0.50 (median 1.4→2.8 mo) with 2-sided log-rank α = 0.05. Other endpoints include overall survival, INV-assessed PFS, objective response rate, safety and translational research. Results: From Oct 2013 to Sep 2014, 156 pts were randomized. Adding P to CT improved PFS (median 4.3 mo vs 2.6 mo for placebo + CT); however, significance was not achieved for the primary endpoint analysis. Subgroup analyses by CT showed inconsistent results. No new safety signals were seen. Conclusion: Although the primary objective was not met, subgroup analyses showed trends favoring P in the GEM and PAC cohorts, potentially explaining the significant findings in one of the sensitivity analyses. These results merit further exploration of P in ovarian cancer. Clinical trial information: NCT01684878. PFS analysis No. of events/pts Stratified HR (95% CI) Primary 126/156 0.74 (0.50–1.11); p = 0.14 Sensitivity IRC in first 109 PFS events 109/156 0.61 (0.39–0.94) IRC backdating PD due to missing tumor assessment 126/156 0.82 (0.55–1.21) CT subgroup, primary GEM 45/53 0.63 (0.34–1.14) PAC 41/54 0.56 (0.29–1.09) TOP* 40/49 1.19 (0.63–2.25) *Recruitment to TOP was slowest.
Invitation to become part of the European Travel Medicine Inventory
Authors: P Schlagenhauf, F Santos O’Connor, P Parola
Journal: Eurosurveillance (2009)

Preview this article: Invitation to become part of the European Travel Medicine Inventory, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/24/art19245-en-1.gif
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Authors: HJ Broxterman, P Sonneveld, R Pieters, J Lankelma, CA Eekman, AH Loonen, M Schoester, GJ Ossenkoppele, B Löwenberg, HM Pinedo, GJ Schuurhuis
Journal: Leukemia (1999)
Urinary Metabolites of the Carcinogen &lt;italic&gt;N&lt;/italic&gt;-2-Fluorenylacetamide&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;,&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: H P MORRIS, E K WEISBURGER, J H WEISBURGER
Journal: JNCI Journal of the National Cancer Institute (1956)
Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single‐institution, retrospective case series
Authors: M. Vaccaro, M. Santarpia, G. Calapai, C. Mannucci, F. Borgia, G. Altavilla, S.P. Cannavò
Journal: British Journal of Dermatology (2016)

Pegylated liposomal doxorubicin (PLD), a chemotherapeutic agent which belongs to the class of anthracyclines, is widely used for treatment of multiple malignancies, including breast cancer, ovarian cancer and Kaposi's sarcoma1-4. Liposomal encapsulation of doxorubicin offers many advantages compared to the soluble, free form of the drug.

This article is protected by copyright. All rights reserved.
PNR-31INHIBITING CELL CYCLE CHECKPOINTS IMPROVES THE EFFICACY OF CHEMOTHERAPY IN PINEOBLASTOMA
Authors: Raelene Endersby, Mani Kuchibhotla, Tobias Schoep, Courtney George, Hilary Hii, Brooke Strowger, Suresh Gande, Ursula Kees, Nick Gottardo
Journal: Neuro-Oncology (2016)
Consumer evaluation of a community mental health service, II: Perceptions of clinical care
Authors: L S Lorefice, J F Borus
Journal: American Journal of Psychiatry (1984)

Using patient self-report and therapist questionnaires, the authors investigated the perceptions of patients at a community mental health service about several aspects of their clinical care: what they expected from treatment, what they found helpful about treatment, how they thought treatment could be improved, their therapist preferences, and their perceptions of their treatment outcome. The patients' desire for advice and the perceived helpfulness of the advice given in therapy, the patients' limited preference for a therapist of their own ethnicity, and other findings are discussed, as is the usefulness of such consumer evaluations in mental health care delivery.
Low–Energy Shockwave Therapy Improves Ischemic Kidney Microcirculation
Authors: Xin Zhang, James D. Krier, Carolina Amador Carrascal, James F. Greenleaf, Behzad Ebrahimi, Ahmad F. Hedayat, Stephen C. Textor, Amir Lerman, Lilach O. Lerman
Journal: Journal of the American Society of Nephrology (2016)

Microvascular rarefaction distal to renal artery stenosis is linked to renal dysfunction and poor outcomes. Low–energy shockwave therapy stimulates angiogenesis, but the effect on the kidney microvasculature is unknown. We hypothesized that low–energy shockwave therapy would restore the microcirculation and alleviate renal dysfunction in renovascular disease. Normal pigs and pigs subjected to 3 weeks of renal artery stenosis were treated with six sessions of low–energy shockwave (biweekly for 3 consecutive weeks) or left untreated. We assessed BP, urinary protein, stenotic renal blood flow, GFR, microvascular structure, and oxygenation in vivo 4 weeks after completion of treatment, and then, we assessed expression of angiogenic factors and mechanotransducers (focal adhesion kinase and β 1-integrin) ex vivo . A 3-week low–energy shockwave regimen attenuated renovascular hypertension, normalized stenotic kidney microvascular density and oxygenation, stabilized function, and alleviated fibrosis in pigs subjected to renal artery stenosis. These effects associated with elevated renal expression of angiogenic factors and mechanotransducers, particularly in proximal tubular cells. In additional pigs with prolonged (6 weeks) renal artery stenosis, shockwave therapy also decreased BP and improved GFR, microvascular density, and oxygenation in the stenotic kidney. This shockwave regimen did not cause detectable kidney injury in normal pigs. In conclusion, low–energy shockwave therapy improves stenotic kidney function, likely in part by mechanotransduction-mediated expression of angiogenic factors in proximal tubular cells, and it may ameliorate renovascular hypertension. Low–energy shockwave therapy may serve as a novel noninvasive intervention in the management of renovascular disease.
Postoperative gas gangrene.
Authors: R M Meltzer, E D Engel, R Turf
Journal: BMJ (1969)

Gas gangrene is a rare complication of elective surgery. Caused by several species of Clostridia, it is an acute, highly invasive necrotizing infection of muscle and fascia often leading to coma and death. Gas gangrene should be suspected if the patient has unremitting pain, high temperature, tachycardia, and prostration. Edema, brown watery exudate emanating from he wound, evidence of gas in tissues, and gram-positive rods on smear support the clinical diagnosis. Rapid surgical decompression and debridement is the basis of treatment. Adjuvant antibiotic, hyperbaric oxygen, antitoxin, local, and supportive therapies aid in treatment. The authors review the literature and discuss etiologies, pathogenesis, clinical features, and treatment.
Proliferation-Related Nucleolar Antigens P145 and P120 Associated with Separate Nucleolar Elements and Differences in Tissue Distribution
Authors: James W. Freeman, Jeffrey E. Hazlewood, Vimala Bondada, Michael L. Cibull, Anna Fonagy, Robert Ochs, Rose K. Busch, Harris Busch
Journal: Cancer Communications (1989)

Nucleolar antigens p145 and p120 are associated with proliferating cells (Freeman, J.W.; McRorie, D.K.; Busch, R.K.; Gyorkey, P.; Gyorkey, F.; Ross, B.E.; Spohn, W.H.; Busch, H. Cancer Res. 46:3593; 1986 and Freeman, J.W.; Busch, R.K.; Gyorkey, P.; Gyorkey, F.; Ross, B.E.; Busch, H. Cancer Res. 48:1244; 1988) and are not detectable in normal resting cells. Recent immunoelectron microscopic studies (Ochs, R.L.; Reilly, M.T.; Freeman, J.W.; Busch, H. Cancer Res. 48:6523; 1988) suggest that the two antigens have overlapping nucleolar localizations. In this study the nucleolus was physicochemically and biochemically studied to determine whether p145 and p120 were associated with a common nucleolar component. Antigen p145 was associated with 40-80 S ribonucleoprotein particles (RNPs), and the p145 antigen was not detected in HeLa cells following in situ RNAse digestion. P120 was found in a 40-80 S, RNAse resistant complex. Sequential extraction of HeLa nucleoli showed that most of antigen p145 was extractable in 10 mM Tris with 0.2% deoxycholate, whereas p120 was found in a nucleolar residue fraction requiring DNAse and high salt treatment for optimal extraction. Neither antigen p145 nor p120 was detectable in normal resting tissues. Antigen p145 was detected in all proliferating tissues examined, including a variety of malignant tumors (ten of ten), benign tissues including adenomas and hyperplasias (eight of eight), and in normal proliferating cells such as colonic epithelium and spermatogonia of the testes. Antigen p120 was not detected in all tumors, being absent in three of seven lymphomas and in one melanoma examined.(ABSTRACT TRUNCATED AT 250 WORDS)
PNR-35CNS HGNET-BCOR - MOLECULAR CHARACTERIZATION AND IDENTIFICATION OF POSSIBLE THERAPEUTIC TARGETS OF A NEW BRAIN TUMOR ENTITY
Authors: Claudia Paret, Johanna Theruvath, Alexandra Russo, Bettina Kron, Khalifa ElMalki, Nadine Lehmann, Marie Neu, Aslihan Gerhold-Ay, Wolfgang Wagner, Clemens Sommer, Larissa Seidmann, Jörg Faber
Journal: Neuro-Oncology (2016)
Elimination of measles
Authors: E. N. Brandt
Journal: JAMA (1982)

To the Editor.—  The elimination of measles as an indigenous disease in this country seems now to be within our reach. By the time this letter is in print, we may have seen at least one week in which no cases of indigenous measles were reported in the United States.  We could not have arrived at this point in our campaign to eliminate measles without the strong support and cooperation ofThe Journalreaders. My purposes in writing are to acknowledge that support—to bring my colleagues up to date on the status of the campaign and to ask for their continued help in the months ahead as we work to make the elimination of measles a permanent reality.  During the past two decades, we have reduced the occurrence of this once common childhood disease from 500,000 cases a year to, last year, just more than 3,000 cases. In the first
The Immune System
Authors: Peter J. Delves, Ivan M. Roitt
Journal: New England Journal of Medicine (2000)

The immune system is an organization of cells and molecules with specialized roles in defending against infection. There are two fundamentally different types of responses to invading microbes. Innate (natural) responses occur to the same extent however many times the infectious agent is encountered, whereas acquired (adaptive) responses improve on repeated exposure to a given infection. The innate responses use phagocytic cells (neutrophils, monocytes, and macrophages), cells that release inflammatory mediators (basophils, mast cells, and eosinophils), and natural killer cells. The molecular components of innate responses include complement, acute-phase proteins, and cytokines such as the interferons. Acquired responses involve the proliferation of . . .
Peripheral vascular disease
Authors: P. J. A. Robinson, A. Parkin
Journal: Clinical Nuclear Medicine (1998)

Occlusive disease of the peripheral arteries is a common cause of morbidity which is likely to increase further in an ageing population. The major underlying pathology is arterial atheroma, the effect of which can be modified and accelerated in patients with systemic hypertension or diabetes. The techniques described below are also applicable in patients with the less common varieties of peripheral arterial disease, including Raynaud's syndrome, vibration white finger, Buerger's disease, inflammatory vasculitides (e.g. Takayasu's disease) and the various vascular entrapment syndromes.
Inheritance of Low Liver Glucuronidase Activity in the Mouse
Authors: L. W. Law, Andrew G. Morrow, Ezra M. Greenspan
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Inheritance of Low Liver Glucuronidase Activity in the Mouse Get access L. W. Law, L. W. Law Clinical Research Unit, U. S. Public Health Service Hospital, Baltimore, Md., and Laboratory of Biology, National Cancer Institute3, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Andrew G. Morrow, Andrew G. Morrow Clinical Research Unit, U. S. Public Health Service Hospital, Baltimore, Md., and Laboratory of Biology, National Cancer Institute3, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Ezra M. Greenspan Ezra M. Greenspan Clinical Research Unit, U. S. Public Health Service Hospital, Baltimore, Md., and Laboratory of Biology, National Cancer Institute3, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 4, February 1952, Pages 909–916, https://doi.org/10.1093/jnci/12.4.909 Published: 01 February 1952 Article history Received: 16 November 1951 Published: 01 February 1952
Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?
Authors: Roberto Latagliata, Ida Carmosino, Federico Vozella, Paola Volpicelli, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, Mauro Nanni, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena
Journal: Blood (2013)
RARE-06ORBITAL OSTEOMA IN CONJUNCTION WITH A CHOLESTEROL GRANULOMA: FIRST REPORTED CASE
Authors: Juanita Garces, Mansour Mathkour, Joshua Hanna, Marcus Ware
Journal: Neuro-Oncology (2015)

INTRODUCTION: Osteomas are the most common facial bone tumor; however primary orbital involvement is extremely rare, especially in the absence of paranasal sinus involvement. Cholesterol granulomas are common lesions that occur in response to cholesterol crystal deposition in tissue and similarly exhibit rare orbital involvement. They may present in a number of structures throughout the body, with orbital involvement being less common. To our knowledge, no prior cases have been reported in the literature of an orbital osteoma co-occurring with a cholesterol granuloma. CASE: A 40-year-old male presented with loss of peripheral vision in his left eye. Examination revealed new onset decreased vision in the left eye with a restrictive visual field to the center of vision. Magnetic resonance imaging (MRI) revealed a mass in the left frontal orbit with associated peripheral enhancement. The lesion produced mass effect on the globe without periorbita or intracranial extension. The patient underwent a left cranio-orbital craniotomy and tumor resection. Pathology revealed numerous foamy and hemosiderin laden macrophages and foreign-body giant cells surrounding cholesterol clefts in a loose fibrous background consistent with the diagnosis of a benign cholesterol granuloma. Adjacent to the granuloma, rounded dense bone with thick trabeculae composed of lamellar bone was identified as an associated osteoma. The patient had an uncomplicated clinical course, with no adjuvant therapy. The patient is presently 4-years post-operation with moderate improvement to his vision and no evidence of recurrence. CONCLUSION: Osteomas and cholesterol granulomas are both benign entities and treatment of each is with surgical resection without adjuvant therapies. Although there are no reports of co-occurrence of these two lesions in the literature, concurrent presentation may be explained by common mechanisms of pathogenesis and their prognosis is favorable.
TB-26TISSUE METABOLITE PROFILES IN THE CHARACTERISATION AND DIAGNOSIS OF CHILDHOOD POSTERIOR FOSSA TUMOURS
Authors: Christopher D. Bennett, Simrandip K. Gill, Sarah Kohe, Niloufar Zarinabad, Nigel P. Davies, Martin Wilson, Lisa Storer, Timothy Ritzmann, Simon Paine, Ian Scott, Ina Nicklaus-Wollenteit, Richard G. Grundy, Andrew C. Peet
Journal: Neuro-Oncology (2016)
The role of echocardiography in the evaluation of mechanical complications of acute myocardial infarction.
Authors: Buda Aj
Journal: Circulation (1991)

With the introduction of the coronary care unit and more effective therapy for primary life-threatening arrhythmias, cardiogenic shock and the mechanical complications of acute myocardial infarction are now responsible for the majority of in-hospital deaths. These mechanical complications, which include myocardial rupture of the left ventricular free wall, rupture of the ventricular septum, and rupture of the papillary muscle, are estimated to account for 25,000 fatalities yearly in the United States. Although the mechanism of myocardial rupture has not been clearly defined, there is increasing evidence that infarct expansion, which can be readily detected by two-dimensional echocardiography, may be an important pathophysiologic factor. The ready availability of echocardiography in the coronary care unit has made a major impact on the immediate diagnosis of mechanical complications in the hemodynamically compromised patient with acute myocardial infarction. In particular, two-dimensional and Doppler echocardiographic techniques have been extremely useful in the identification and localization of ventricular septal rupture. In addition, papillary muscle rupture can be readily diagnosed by Doppler approaches and is easily distinguished from ventricular septal rupture. In view of increasing evidence that early surgical intervention is indicated in these patients, these echocardiographic approaches offer the surgeon prompt diagnostic and anatomic information. Unfortunately, rupture of the free wall of the left ventricle often results in sudden death within minutes before echocardiographic evaluation can be attempted. Nevertheless, rapid echocardiographic diagnosis provides the patient with the possibility of potential life-saving resuscitative interventions before immediate surgery. Thus, over the past decade, echocardiography has become a vital tool in the diagnosis and evaluation of patients with mechanical complications of acute myocardial infarction. The development of Doppler techniques, color flow Doppler, and esophageal approaches should further enhance our diagnostic abilities and allow careful monitoring of patients before, during, and after surgical repair. It is hoped that with the improvements in echocardiographic evaluation of mechanical rupture and more rapid surgical intervention, future studies will demonstrate better surgical results with good long-term survival in patients with myocardial rupture.
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Authors: Koichi Goto, Yuichiro Ohe, Taro Shibata, Takashi Seto, Toshiaki Takahashi, Kazuhiko Nakagawa, Hiroshi Tanaka, Koji Takeda, Makoto Nishio, Kiyoshi Mori, Miyako Satouchi, Toyoaki Hida, Naruo Yoshimura, Toshiyuki Kozuki, Fumio Imamura, Katsuyuki Kiura, Hiroaki Okamoto, Toshiyuki Sawa, Tomohide Tamura
Journal: The Lancet Oncology (2016)
Neoplasms in Hamsters Induced by Mouse Tumor Agent Passed in Tissue Culture
Authors: Bernice E. Eddy, Sarah E. Stewart, Ralph Young, G. Burroughs Mider
Journal: JNCI Journal of the National Cancer Institute (1958)

Neoplasms in Hamsters Induced by Mouse Tumor Agent Passed in Tissue Culture Get access Bernice E. Eddy, Bernice E. Eddy Division of Biologics Standards2 and National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Sarah E. Stewart, Sarah E. Stewart Division of Biologics Standards2 and National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Ralph Young, Ralph Young Division of Biologics Standards2 and National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Burroughs Mider G. Burroughs Mider Division of Biologics Standards2 and National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 4, April 1958, Pages 747–761, https://doi.org/10.1093/jnci/20.4.747 Published: 01 April 1958 Article history Received: 17 October 1957 Published: 01 April 1958
Isolated Follicle-Stimulating Hormone Deficiency Revisited
Authors: David Rabinowitz, Robert Benveniste, Jill Lindner, Daniel Lorber, James Daniell
Journal: New England Journal of Medicine (1979)

WE have previously described the clinical features of a 22-year-old woman who was evaluated in 1971 for primary amenorrhea and in whom we established the diagnosis of isolated deficiency of follicle-stimulating hormone (FSH).1,2 Serum FSH levels were undetectable, whereas luteinizing hormone (LH) levels were in the postmenopausal range (50 to 90 mIU per milliliter). She had received two courses of therapy with human menopausal gonadotropins (menotropins), after which we detected human anti-FSH antibody in her serum.We now report the successful induction of ovulation and conception, with subsequent uneventful pregnancy, in this unique patient with isolated FSH deficiency and anti-FSH . . .